Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Armodafinil (Nuvigil) wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Armodafinil (Nuvigil) and Modafinil have evidence — compare verdict strength side-by-side.
Approved dosing is 150–250 mg once daily in the morning for narcolepsy and OSA, or 150 mg taken ~1 hour before the start of a night shift for shift-work disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.
morning
Oral tablet (armodafinil)
Approved dosing is 200 mg once daily in the morning for narcolepsy and OSA, or 200 mg taken ~1 hour before the start of a night shift for shift-work sleep disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.
morning
Oral tablet (modafinil)
Hours (per dose); weeks for steady benefit
Per dose (acute)
Acute / weeks
Throughout use
Hours (per dose); weeks for steady benefit
Per dose (acute)
Acute
Throughout use
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.
Current medical research and opinion (2006) · Rct · n=196
Pivotal 12-week, multicenter, double-blind, placebo-controlled RCT in 196 narcolepsy patients (armodafinil 150 mg, 250 mg, or placebo once daily)
Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
Clinical therapeutics (2006) · Rct
12-week, 37-center, double-blind, placebo-controlled RCT of armodafinil 150 or 250 mg as adjunct in nCPAP-adherent OSA/hypopnea patients with residual excessive sleepiness
Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study.
Mayo Clinic proceedings (2009) · Rct · n=254
12-week, 42-site, randomized, double-blind, placebo-controlled RCT in 254 night-shift workers with moderate-or-greater shift work disorder (armodafinil 150 mg vs placebo before each shift)
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group.
Annals of neurology (1998) · Rct · n=283
Pivotal placebo-controlled, double-blind, 18-center RCT in 283 narcolepsy patients (modafinil 200 or 400 mg vs placebo)
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group.
Neurology (2000) · Rct · n=271
Second pivotal 9-week, placebo-controlled, double-blind, 21-center RCT (n=271; 200 or 400 mg vs placebo)
Modafinil for excessive sleepiness associated with shift-work sleep disorder.
The New England journal of medicine (2005) · Rct · n=209
3-month double-blind RCT of 200 mg modafinil before each night shift vs placebo in 209 shift-work-sleep-disorder patients (NEJM)
Armodafinil (Nuvigil) has a higher evidence score (5/10 vs 5/10) and wins in 1 of 3 categories.
No known interactions between Armodafinil (Nuvigil) and Modafinil have been documented in our database. However, always consult a healthcare provider before combining supplements.